Sonoma Pharmaceuticals (SNOA) Competitors $4.60 -0.23 (-4.67%) Closing price 03:58 PM EasternExtended Trading$4.62 +0.03 (+0.54%) As of 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNOA vs. ESLA, SCYX, RNXT, AKTX, CLSD, MURA, BTAI, MAAQ, SNYR, and DYAIShould you be buying Sonoma Pharmaceuticals stock or one of its competitors? The main competitors of Sonoma Pharmaceuticals include Estrella Immunopharma (ESLA), SCYNEXIS (SCYX), RenovoRx (RNXT), Akari Therapeutics (AKTX), Clearside Biomedical (CLSD), Mural Oncology (MURA), BioXcel Therapeutics (BTAI), Mana Capital Acquisition (MAAQ), Synergy CHC (SNYR), and Dyadic International (DYAI). These companies are all part of the "pharmaceutical products" industry. Sonoma Pharmaceuticals vs. Its Competitors Estrella Immunopharma SCYNEXIS RenovoRx Akari Therapeutics Clearside Biomedical Mural Oncology BioXcel Therapeutics Mana Capital Acquisition Synergy CHC Dyadic International Estrella Immunopharma (NASDAQ:ESLA) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership. Is ESLA or SNOA more profitable? Estrella Immunopharma has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -23.87%. Sonoma Pharmaceuticals' return on equity of -50.00% beat Estrella Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Estrella ImmunopharmaN/A -1,132.38% -358.54% Sonoma Pharmaceuticals -23.87%-50.00%-16.79% Which has more risk and volatility, ESLA or SNOA? Estrella Immunopharma has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500. Comparatively, Sonoma Pharmaceuticals has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Do analysts rate ESLA or SNOA? Estrella Immunopharma presently has a consensus target price of $16.00, indicating a potential upside of 1,558.03%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Estrella Immunopharma is more favorable than Sonoma Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Sonoma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders believe in ESLA or SNOA? 0.4% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 55.1% of Estrella Immunopharma shares are owned by company insiders. Comparatively, 24.6% of Sonoma Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has higher earnings & valuation, ESLA or SNOA? Estrella Immunopharma has higher earnings, but lower revenue than Sonoma Pharmaceuticals. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEstrella ImmunopharmaN/AN/AN/A-$0.26-3.71Sonoma Pharmaceuticals$14.29M0.53-$3.46M-$2.46-1.87 Does the media refer more to ESLA or SNOA? In the previous week, Estrella Immunopharma and Estrella Immunopharma both had 1 articles in the media. Sonoma Pharmaceuticals' average media sentiment score of 0.96 beat Estrella Immunopharma's score of 0.93 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Estrella Immunopharma Positive Sonoma Pharmaceuticals Positive SummarySonoma Pharmaceuticals beats Estrella Immunopharma on 7 of the 13 factors compared between the two stocks. Get Sonoma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNOA vs. The Competition Export to ExcelMetricSonoma PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.54M$2.48B$5.75B$9.78BDividend YieldN/A1.67%4.40%4.04%P/E Ratio-1.8722.5330.8326.41Price / Sales0.53507.79383.2586.73Price / CashN/A178.3537.7259.11Price / Book1.866.2910.116.65Net Income-$3.46M$32.94M$3.26B$265.42M7 Day Performance-9.72%2.50%3.71%3.55%1 Month Performance34.36%1.28%3.82%0.53%1 Year Performance2,018.49%5.87%37.79%19.50% Sonoma Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNOASonoma PharmaceuticalsN/A$4.60-4.7%N/A+1,952.8%$7.54M$14.29M-1.87180Positive NewsGap DownESLAEstrella Immunopharma2.8626 of 5 stars$0.94+2.7%$16.00+1,611.2%-22.4%$34.66MN/A-3.60N/AGap DownSCYXSCYNEXIS1.1399 of 5 stars$0.83+2.8%N/A-47.8%$34.58M$3.75M-2.0660RNXTRenovoRx3.0237 of 5 stars$0.94+0.1%$7.25+670.5%-4.0%$34.41M$40K-2.486Analyst ForecastAKTXAkari Therapeutics3.0488 of 5 stars$1.00flat$5.00+400.0%-76.9%$32.18MN/A0.009Positive NewsCLSDClearside Biomedical2.6696 of 5 stars$0.40-5.8%$4.20+947.4%-60.9%$31.48M$4.17M-1.0830News CoveragePositive NewsMURAMural Oncology2.9137 of 5 stars$1.77-2.7%$12.00+578.0%-39.4%$30.84MN/A-0.21119BTAIBioXcel Therapeutics4.5486 of 5 stars$4.95-12.8%$39.75+703.7%-53.7%$29.72M$2.27M-0.3990Trending NewsGap DownTrading HaltedMAAQMana Capital AcquisitionN/A$3.63-9.8%N/A-38.6%$29.49MN/A0.001SNYRSynergy CHC4.3515 of 5 stars$3.18-8.6%$10.00+214.5%+2,200.0%$29.24M$33.70M8.3740DYAIDyadic International3.4144 of 5 stars$0.80+0.5%$6.00+650.9%-37.6%$28.92M$3.49M-4.217Positive News Related Companies and Tools Related Companies Estrella Immunopharma Competitors SCYNEXIS Competitors RenovoRx Competitors Akari Therapeutics Competitors Clearside Biomedical Competitors Mural Oncology Competitors BioXcel Therapeutics Competitors Mana Capital Acquisition Competitors Synergy CHC Competitors Dyadic International Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNOA) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonoma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonoma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access